Anticoagulants: Global Strategic Business Report

Global Anticoagulants Market to Reach $74.3 Billion by 2030

The global market for Anticoagulants estimated at US$38.1 Billion in the year 2022, is projected to reach a revised size of US$74.3 Billion by 2030, growing at a CAGR of 8.7% over the analysis period 2022-2030. NOACs, one of the segments analyzed in the report, is projected to record 10.9% CAGR and reach US$33.4 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Xarelto segment is readjusted to a revised 6.2% CAGR for the next 8-year period.

The U.S. Market is Estimated at $10.4 Billion, While China is Forecast to Grow at 15.4% CAGR

The Anticoagulants market in the U.S. is estimated at US$10.4 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$20.1 Billion by the year 2030 trailing a CAGR of 15.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.6% and 7.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Select Competitors (Total 48 Featured) -

• Abbott India Limited
• Aspen Holdings
• Bayer Healthcare AG
• Boehringer Ingelheim
• Bristol-Myers Squibb Company
• Mitsubishi Tanabe Pharma Corp.
• Pfizer Inc.
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and Research Platform
• Complimentary updates for one year